SCHEMBL5790197

SCHEMBL5790197

C[C](C)Cc1cccc(N2CCN(C)CC2)c1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AGXT P21549 2/20 0.61
ADRA2C P18825 1/20 0.56
HTR3A P46098 1/20 0.46
ITGB3 P05106 1/20 0.46
ITGA2B P08514 1/20 0.46
PLOD2 O00469 1/20 0.46
PLOD3 O60568 1/20 0.46
PLOD1 Q02809 1/20 0.46
PRMT6 Q96LA8 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
DRD2 P14416 2/20 0.44
HTR6 P50406 1/20 0.44
DRD3 P35462 1/20 0.43
CHKA P35790 1/20 0.43
MAPK14 Q16539 1/20 0.43
OPRM1 P35372 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4576036 0.87 PRMT6 (0.59) AGXTITGB3ITGA2BPRMT6DRD2
SCHEMBL20425007 0.84 ITGB3 (0.64) AGXTADRA2CITGB3ITGA2BPLOD2
SCHEMBL4577571 0.84 CHRNA7 (0.56) AGXTITGB3ITGA2BNPC1RAB9A
SCHEMBL11891932 0.83 AGXT (0.65) AGXTADRA2CHTR3APLOD2PLOD3
SCHEMBL4577356 0.83 KDM4E (0.47) AGXTITGB3ITGA2BPRMT6DRD2
SCHEMBL5790195 0.83 AGXT (0.61) AGXTADRA2CITGB3ITGA2BPLOD2
SCHEMBL28739636 0.83 ITGB3 (0.62) AGXTADRA2CITGB3ITGA2BPLOD2
SCHEMBL17890851 0.83 AGXT (0.57) AGXTADRA2CITGB3ITGA2BPLOD2
SCHEMBL4577257 0.83 DRD2 (0.50) AGXTDRD2DRD3OPRM1
SCHEMBL8222798 0.82 AGXT (0.63) AGXTADRA2CHTR3APRMT6DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1549717-B Cysteine protease inhibitors having 2-cyano-4-aminopyrimidine structure and cathepsin K inhibitory activity and pharmaceutical use thereof NOVARTIS AG 2011-08-17 CN disclosed
EP-1423121-B1 CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES NOVARTIS AG (CH) 2006-11-15 EP disclosed
US-7112589-B2 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases NOVARTIS AG (CH) 2006-09-26 US disclosed
US-20060074092-A1 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases ALTMANN EVA 2006-04-06 US disclosed
US-20040249153-A1 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases NOVARTIS AG (CH) 2004-12-09 US disclosed
CN-1549717-A Cysteine protease inhibitors having 2-cyano-4-aminopyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammation and other diseases ��˹��ŵ�� 2004-11-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040249153-A1 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases CTSK, CTSS, CTSZ AGXT 1279/4885ADRA2C 3219/4885HTR3A 3982/4885
US-20060074092-A1 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases CTSK, CTSS, CTSZ AGXT 1197/4885ADRA2C 3283/4885HTR3A 4108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.